Detalhe da pesquisa
1.
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Gynecol Oncol
; 186: 42-52, 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582027
2.
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Gynecol Oncol
; 177: 86-94, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657193
3.
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Gynecol Oncol
; 178: 80-88, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820398
4.
Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
Gynecol Oncol
; 176: 162-172, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556934
5.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer
; 33(9): 1331-1344, 2023 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591609
6.
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
Br J Cancer
; 127(3): 488-499, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35501389
7.
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
J Pathol
; 253(1): 41-54, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32901952
8.
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Gynecol Oncol
; 157(1): 12-20, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954537
9.
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Gynecol Oncol
; 157(1): 36-45, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001076
10.
Low-grade serous ovarian cancer: State of the science.
Gynecol Oncol
; 156(3): 715-725, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969252
11.
Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers.
Int J Gynecol Cancer
; 30(6): 783-788, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32354793
12.
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Cancer Cell Int
; 19: 10, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30636931
13.
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Gynecol Oncol
; 152(3): 459-464, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30876489
14.
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Gynecol Oncol
; 146(2): 319-326, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28545687
15.
Corrigendum to "Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes" [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36-45].
Gynecol Oncol
; 167(2): 399, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850594
16.
Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.
J Natl Compr Canc Netw
; 15(8): 1015-1021, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28784863
17.
Long-term consequences of ovarian ablation for premenopausal breast cancer.
Breast Cancer Res Treat
; 157(3): 565-73, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27236562
18.
BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.
Int J Gynecol Cancer
; 26(5): 825-32, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27051059
19.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncol
; 16(8): 928-36, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26115797
20.
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.
Mol Cancer
; 13: 241, 2014 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25344116